Amgen Total Assets Growth & History (AMGN)
Amgen's total assets was $90.59B for fiscal 2025.
View full Amgen company overviewAmgen annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $90.59B | −$1.25B | −1.36% |
| 2024 | 2024-12-31 | $91.84B | −$5.32B | −5.47% |
| 2023 | 2023-12-31 | $97.15B | $32.03B | +49.19% |
| 2022 | 2022-12-31 | $65.12B | $3.96B | +6.47% |
| 2021 | 2021-12-31 | $61.16B | −$1.78B | −2.83% |
| 2020 | 2020-12-31 | $62.95B | $3.24B | +5.43% |
| 2019 | 2019-12-31 | $59.71B | −$6.71B | −10.10% |
| 2018 | 2018-12-31 | $66.42B | −$13.54B | −16.93% |
| 2017 | 2017-12-31 | $79.95B | $2.33B | +3.00% |
| 2016 | 2016-12-31 | $77.63B | $6.18B | +8.65% |
| 2015 | 2015-12-31 | $71.45B | $2.44B | +3.54% |
| 2014 | 2014-12-31 | $69.01B | $2.88B | +4.36% |
| 2013 | 2013-12-31 | $66.13B | $11.83B | +21.78% |
| 2012 | 2012-12-31 | $54.30B | $5.43B | +11.10% |
| 2011 | 2011-12-31 | $48.87B | $5.38B | +12.38% |
| 2010 | 2010-12-31 | $43.49B | $3.86B | +9.73% |
| 2009 | 2009-12-31 | $39.63B | $3.20B | +8.79% |
| 2008 | 2008-12-31 | $36.43B | — | — |
Amgen quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $95.64B | $7.74B | +8.81% |
| Q1 2026 | 2026-03-31 | $92.50B | $3.14B | +3.51% |
| Q4 2025 | 2025-12-31 | $90.59B | −$1.25B | −1.36% |
| Q3 2025 | 2025-09-30 | $90.14B | −$742.0M | −0.82% |
| Q2 2025 | 2025-06-30 | $87.90B | −$3.01B | −3.31% |
| Q1 2025 | 2025-03-31 | $89.37B | −$3.61B | −3.89% |
| Q4 2024 | 2024-12-31 | $91.84B | −$5.32B | −5.47% |
| Q3 2024 | 2024-09-30 | $90.88B | $349.0M | +0.39% |
| Q2 2024 | 2024-06-30 | $90.91B | $638.0M | +0.71% |
| Q1 2024 | 2024-03-31 | $92.98B | $4.26B | +4.80% |
| Q4 2023 | 2023-12-31 | $97.15B | $32.03B | +49.19% |
| Q3 2023 | 2023-09-30 | $90.53B | $26.83B | +42.13% |
| Q2 2023 | 2023-06-30 | $90.27B | $30.98B | +52.24% |
| Q1 2023 | 2023-03-31 | $88.72B | $29.52B | +49.87% |
| Q4 2022 | 2022-12-31 | $65.12B | $3.96B | +6.47% |
| Q3 2022 | 2022-09-30 | $63.70B | −$1.29B | −1.99% |
| Q2 2022 | 2022-06-30 | $59.29B | — | — |
| Q1 2022 | 2022-03-31 | $59.20B | −$3.34B | −5.35% |
| Q4 2021 | 2021-12-31 | $61.16B | −$1.78B | −2.83% |
| Q3 2021 | 2021-09-30 | $64.99B | $356.0M | +0.55% |
| Q1 2021 | 2021-03-31 | $62.54B | $870.0M | +1.41% |
| Q4 2020 | 2020-12-31 | $62.95B | $3.24B | +5.43% |
| Q3 2020 | 2020-09-30 | $64.64B | — | — |
| Q2 2020 | 2020-06-30 | $65.01B | $5.64B | +9.50% |
| Q1 2020 | 2020-03-31 | $61.67B | −$2.33B | −3.64% |
| Q4 2019 | 2019-12-31 | $59.71B | −$6.71B | −10.10% |
| Q2 2019 | 2019-06-30 | $59.37B | −$8.31B | −12.28% |
| Q1 2019 | 2019-03-31 | $64.00B | −$7.17B | −10.07% |
| Q4 2018 | 2018-12-31 | $66.42B | −$13.54B | −16.93% |
| Q3 2018 | 2018-09-30 | $67.33B | −$13.00B | −16.18% |
| Q2 2018 | 2018-06-30 | $67.68B | −$11.90B | −14.96% |
| Q1 2018 | 2018-03-31 | $71.16B | −$6.70B | −8.60% |
| Q4 2017 | 2017-12-31 | $79.95B | $2.33B | +3.00% |
| Q3 2017 | 2017-09-30 | $80.33B | $2.18B | +2.79% |
| Q2 2017 | 2017-06-30 | $79.59B | $4.12B | +5.45% |
| Q1 2017 | 2017-03-31 | $77.86B | $2.75B | +3.66% |
| Q4 2016 | 2016-12-31 | $77.63B | $6.18B | +8.65% |
| Q3 2016 | 2016-09-30 | $78.15B | $6.28B | +8.74% |
| Q2 2016 | 2016-06-30 | $75.47B | $4.26B | +5.99% |
| Q1 2016 | 2016-03-31 | $75.12B | $6.16B | +8.94% |
| Q4 2015 | 2015-12-31 | $71.45B | $2.44B | +3.54% |
| Q3 2015 | 2015-09-30 | $71.87B | $1.09B | +1.55% |
| Q2 2015 | 2015-06-30 | $71.21B | $1.68B | +2.41% |
| Q1 2015 | 2015-03-31 | $68.95B | $1.95B | +2.91% |
| Q4 2014 | 2014-12-31 | $69.01B | $2.88B | +4.36% |
| Q3 2014 | 2014-09-30 | $70.78B | $13.70B | +24.01% |
| Q2 2014 | 2014-06-30 | $69.53B | — | — |
| Q1 2014 | 2014-03-31 | $67.00B | $15.36B | +29.75% |
| Q4 2013 | 2013-12-31 | $66.13B | $11.83B | +21.78% |
| Q3 2013 | 2013-09-30 | $57.07B | — | — |
| Q1 2013 | 2013-03-31 | $51.64B | — | — |
| Q4 2012 | 2012-12-31 | $54.30B | $5.43B | +11.10% |
| Q4 2011 | 2011-12-31 | $48.87B | $5.38B | +12.38% |
| Q1 2011 | 2011-03-31 | $42.71B | $2.35B | +5.82% |
| Q4 2010 | 2010-12-31 | $43.49B | $3.86B | +9.73% |
| Q3 2010 | 2010-09-30 | $43.53B | $2.59B | +6.34% |
| Q2 2010 | 2010-06-30 | $40.80B | $1.96B | +5.05% |
| Q1 2010 | 2010-03-31 | $40.37B | — | — |
| Q4 2009 | 2009-12-31 | $39.63B | $3.20B | +8.79% |
| Q3 2009 | 2009-09-30 | $40.94B | — | — |
| Q2 2009 | 2009-06-30 | $38.84B | — | — |
| Q4 2008 | 2008-12-31 | $36.43B | — | — |
Amgen total assets trends
Over the last five fiscal years, Amgen's total assets increased from $62.95B to $90.59B, a change of $27.64B. The latest reported quarter, Q2 2026, shows $95.64B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗